ProPhase Labs, Inc. (PRPH)
| Market Cap | 84.05M |
| Revenue (ttm) | 14.51M |
| Net Income (ttm) | -2.13M |
| Shares Out | 15.15M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | 2.51 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $5.53 |
| Previous Close | $5.60 |
| Change ($) | -0.07 |
| Change (%) | -1.25% |
| Day's Open | 5.68 |
| Day's Range | 5.45 - 5.80 |
| Day's Volume | 50,671 |
| 52-Week Range | 1.20 - 16.04 |
GARDEN CITY, NY, April 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Thursday, May 13, 2021 at 4:3...
Recent Acquisition of Digital COVID-19 Vaccination and Testing “Passport” Transforms the Company's Portal Into a Universal Digital Certificate Solution and Uniquely Positions Company for Re-Opening Phas...
Shares of ProPhase Labs Inc (NASDAQ: PRPH), a consumer healthcare and diagnostics company, jumped 32% in the extended session on Tuesday. What Happened: ProPhase said on Tuesday it has acquired mobile a...
New Reporting App Simplifies Documentation of User Vaccination and Covid Testing Statue – Easily Enables Clear Access to Air/Rail/Bus Travel, Concert & Sporting Events
GARDEN CITY, NY, March 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Wednesday, March 31, 2021 at ...
ProPhase Labs, Inc (NASDAQ:PRPH) is one of three emerging companies that will present at Proactive's virtual investor conference on Tuesday, February 16. Hosted by Proactive's Christine Corrado, the eve...
Company Integrates Spectrum Solutions™ SDNA-1000 Saliva Collection System for Advanced, Simultaneous Multi-Viral Detection of Infections and Viral Mutations
Company to Host Business Update Shareholder's Conference Call on February 10, 2021 at 11:00 a.m. Eastern Time
- Total Company Processing Capacity On Track to Reach 60,000 Tests Per Day –
Garden City, NY, Jan. 21, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced the closing of its previously announced publi...
GARDEN CITY, NY, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today the pricing of an underwritten public offerin...
GARDEN CITY, NY, Jan. 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has commenced a proposed underwritten...
Company Exceeding Near Term Goals & Expands 2021 Testing Capacity
GARDEN CITY, NY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced that it has entered into a definitive securit...
Company Expands to Meet Anticipated Demand for Increased Molecular Testing From New Business Opportunities – Aiming For Capacity to Process 50,000 Tests per Day
DOYLESTOWN, Pennsylvania, Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced net sales of $3.8 million for the th...
DOYLESTOWN, PA , Nov. 10, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase Labs”), a diversified medical science and technology company, today announced that management will presen...
DOYLESTOWN, Pennsylvania, Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has completed the acquisitio...
DOYLESTOWN, Pennsylvania, Oct. 23, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today a definitive agreement to acquire a ...
Company Enters into Consulting Agreement and Amended and Restated Promissory Note and Security Agreement with Predictive Laboratories, Inc. to Further These Plans
DOYLESTOWN, Pennsylvania, Sept. 30, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, has engaged international investor relations specia...
DOYLESTOWN, Pennsylvania, Sept. 23, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com ) today announced that it has entered into an at-the-market (“ATM”) equity offerin...
DOYLESTOWN, Pennsylvania, Sept. 18, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced that it has closed on a $10 million unsecured debt financing. The ...
DOYLESTOWN, Pennsylvania, Aug. 11, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced net sales of $3.6 million for the three months ended June 30, 2020,...
DOYLESTOWN, Pennsylvania, May 12, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com ) today announced net sales of $1.9 million for the three months ended March 31, 202...
DOYLESTOWN, Pennsylvania, March 25, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced its net sales were $9.9 million for the year ended December 31, 20...
DOYLESTOWN, PA, Nov. 20, 2019 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com), a vertically integrated manufacturer, marketer and distributor of a diversified range of ove...
ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today reported net sales of $2.8 million for the three months ended September 30, 2019 compared to net sales of $2.4 million for the three months...
About PRPH
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product developme... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jan 16, 1997 |
| Stock Exchange NASDAQ | Ticker Symbol PRPH |
Financial Performance
In 2020, ProPhase Labs's revenue was $14.51 million, an increase of 46.96% compared to the previous year's $9.88 million. Losses were -$2.13 million, -32.45% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for ProPhase Labs stock is "Strong Buy" and the 12-month stock price forecast is 22.50.